12 September 2019
Coulter Partners secures Non-Executive Director for Nanoform
Coulter Partners was very pleased to partner once more with innovative medicine enabling nanotechnology company, Nanoform to secure the appointment of Mads Laustsen as a non-executive board member. This appointment will further strengthen the experienced Nanoform board and support the company as it increases its ability to deliver nanonized APIs for global partners across the pipeline from late stage drug discovery to commercial.
Mads Laustsen has over 30 years’ experience in pharmaceutical development and manufacturing. As co-founder and CEO of the international biologics contract manufacturing organization CMC Biologics, he was responsible for the creation, development and operation of facilities both in Europe and the US. He has extensive experience in process development and patenting, and holds senior positions within a number of Danish biotechnology companies, including Synklino, Bactolife and Symphogen.
The appointment of Mads Laustsen to the board coincides with the rapid construction progress of Nanoform’s GMP manufacturing plant. The increased capacity, combined with Mads’ deep knowledge of manufacturing development, will enable Nanoform to achieve its aim of doubling the number of drug compounds that successfully reach the market and adding value to Pharma clients existing pipelines.
Edward Hæggström, CEO of Nanoform said: “It gives me great pleasure to welcome Mads Laustsen to the Nanoform board. Mads is an exceptional entrepreneur with vast experience in the provision of GMP facilities and infrastructures. His outstanding experience will be incredibly valuable as we expand our manufacturing capacity and I thank the highly professional team at Coulter Partners for helping us once more to achieve such a quality appointment.”
Mads Laustsen added: “I am excited to be joining the Nanoform board as the company prepares to further international commercialization of its best-in-class nanonization technology. I look forward to working with the ambitious and skilled Nanoform team as they enable more patients around the world to benefit from enhanced drug therapies.”
Nanoform is an innovative nanoparticle medicine enabling company. Nanoform works together with pharma and biotech partners globally to reduce clinical attrition and enhance their molecules formulation performance through its best-in-class nanonization™services. The company’s multi-patented and scalable Controlled Expansion of Supercritical Solutions (CESS®) technology produces nanonized “designed-for-purpose” API particles, as small as 10nm. This enables poorly soluble molecules in the pharmaceutical pipeline to progress into clinical development by increasing their rate of dissolution and improving their bioavailability. Nanoform’s unique nanonization™ technology provides novel opportunities in diverse value enhancing drug delivery applications.
For more information about Nanoform, please visit www.nanoform.fi
Top global hires for large-cap, mid-cap and public companies H2-2022
15 December 2022
Top global hires for large-cap, mid-cap and public companies
07 June 2022
Top hires for VC & PE portfolio companies Q2-2021
27 July 2021
Top hires for VC & PE portfolio companies Q3-2020
22 October 2020